JP2017506506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506506A5 JP2017506506A5 JP2016550631A JP2016550631A JP2017506506A5 JP 2017506506 A5 JP2017506506 A5 JP 2017506506A5 JP 2016550631 A JP2016550631 A JP 2016550631A JP 2016550631 A JP2016550631 A JP 2016550631A JP 2017506506 A5 JP2017506506 A5 JP 2017506506A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- biomarker
- subject
- score
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 72
- 238000000034 method Methods 0.000 claims 44
- 239000002246 antineoplastic agent Substances 0.000 claims 28
- 229940127089 cytotoxic agent Drugs 0.000 claims 27
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 206010033128 Ovarian cancer Diseases 0.000 claims 14
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 14
- -1 CXCR2P1 Proteins 0.000 claims 12
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 12
- 102100023915 Insulin Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 230000001772 anti-angiogenic effect Effects 0.000 claims 10
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 8
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 claims 8
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 8
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims 8
- 101000831866 Homo sapiens Transmembrane protein 45A Proteins 0.000 claims 8
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 8
- 108010072582 Matrilin Proteins Proteins 0.000 claims 8
- 102000055008 Matrilin Proteins Human genes 0.000 claims 8
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims 8
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims 8
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims 8
- 102100024186 Transmembrane protein 45A Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229960000397 bevacizumab Drugs 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 7
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 102100039435 C-X-C motif chemokine 17 Human genes 0.000 claims 4
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 claims 4
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 claims 4
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 claims 4
- 101000575378 Homo sapiens Microfibrillar-associated protein 2 Proteins 0.000 claims 4
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 claims 4
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims 4
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 4
- 102100025599 Microfibrillar-associated protein 2 Human genes 0.000 claims 4
- 101100274957 Mus musculus Col1a1 gene Proteins 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 claims 4
- 108091006277 SLC5A1 Proteins 0.000 claims 4
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 4
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 3
- 239000003080 antimitotic agent Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 2
- 229960002412 cediranib Drugs 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 claims 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102000003916 Arrestin Human genes 0.000 claims 1
- 108090000328 Arrestin Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 102400000730 Canstatin Human genes 0.000 claims 1
- 101800000626 Canstatin Proteins 0.000 claims 1
- 102100031186 Chromogranin-A Human genes 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 229950003968 motesanib Drugs 0.000 claims 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 238000007637 random forest analysis Methods 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229940034785 sutent Drugs 0.000 claims 1
- 229940069905 tasigna Drugs 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229960000940 tivozanib Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 108010075758 trebananib Proteins 0.000 claims 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims 1
- 108010060757 vasostatin Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937224P | 2014-02-07 | 2014-02-07 | |
| US61/937,224 | 2014-02-07 | ||
| GBGB1409479.1A GB201409479D0 (en) | 2014-05-28 | 2014-05-28 | Molecular diagnostic test for cancer |
| GB1409479.1 | 2014-05-28 | ||
| PCT/GB2015/050352 WO2015118353A1 (en) | 2014-02-07 | 2015-02-09 | Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506506A JP2017506506A (ja) | 2017-03-09 |
| JP2017506506A5 true JP2017506506A5 (enExample) | 2018-03-15 |
Family
ID=51177582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550631A Pending JP2017506506A (ja) | 2014-02-07 | 2015-02-09 | 抗血管新生薬への応答およびがんの予後の予測のための分子診断試験 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10280468B2 (enExample) |
| EP (1) | EP3102700A1 (enExample) |
| JP (1) | JP2017506506A (enExample) |
| KR (1) | KR20160117606A (enExample) |
| CN (1) | CN106164296A (enExample) |
| AU (1) | AU2015213844A1 (enExample) |
| BR (1) | BR112016018044A2 (enExample) |
| CA (1) | CA2938807A1 (enExample) |
| GB (1) | GB201409479D0 (enExample) |
| WO (1) | WO2015118353A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11568982B1 (en) | 2014-02-17 | 2023-01-31 | Health at Scale Corporation | System to improve the logistics of clinical care by selectively matching patients to providers |
| US10650325B2 (en) * | 2015-07-31 | 2020-05-12 | Microsoft Technology Licensing, Llc | Deterministic message distribution |
| US10496691B1 (en) | 2015-09-08 | 2019-12-03 | Google Llc | Clustering search results |
| WO2018062862A1 (ko) * | 2016-09-28 | 2018-04-05 | 가톨릭대학교 산학협력단 | 신장암 환자의 예후 진단 및 치료 전략 결정용 성별 특이적 마커 |
| WO2018124153A1 (ja) * | 2016-12-28 | 2018-07-05 | 公益財団法人がん研究会 | 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット |
| CN107301328B (zh) * | 2017-05-19 | 2021-04-06 | 浙江工业大学 | 基于数据流聚类的癌症亚型精准发现与演化分析方法 |
| CN111033631B (zh) * | 2017-06-13 | 2024-03-12 | 波士顿基因公司 | 用于生成分子功能谱、对其进行可视化和分类的系统和方法 |
| JP6977965B2 (ja) * | 2017-10-26 | 2021-12-08 | 公立大学法人福島県立医科大学 | 卵巣癌組織型鑑別方法 |
| CN110880356A (zh) * | 2018-09-05 | 2020-03-13 | 南京格致基因生物科技有限公司 | 对卵巢癌进行筛查、诊断或风险分级的方法和装置 |
| WO2020092808A1 (en) * | 2018-10-31 | 2020-05-07 | Regents Of The University Of Minnesota | Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer |
| US11610679B1 (en) | 2020-04-20 | 2023-03-21 | Health at Scale Corporation | Prediction and prevention of medical events using machine-learning algorithms |
| CN112164474B (zh) * | 2020-07-14 | 2024-05-24 | 中国矿业大学 | 一种基于自表达模型的药物敏感性预测方法 |
| US12094582B1 (en) | 2020-08-11 | 2024-09-17 | Health at Scale Corporation | Intelligent healthcare data fabric system |
| US12080428B1 (en) | 2020-09-10 | 2024-09-03 | Health at Scale Corporation | Machine intelligence-based prioritization of non-emergent procedures and visits |
| US20240344138A1 (en) * | 2021-03-25 | 2024-10-17 | Feng Biosciences, Inc | Targeted therapies in cancer |
| WO2022256743A1 (en) * | 2021-06-04 | 2022-12-08 | Cedars-Sinai Medical Center | Use of cancer cell expression of cadherin 12 and cadherin 18 to treat bladder cancers |
| CN113667752A (zh) * | 2021-09-09 | 2021-11-19 | 菲思特(上海)生物科技有限公司 | 一种用于柔红霉素代谢标志物的检测试剂盒及其检测方法和应用 |
| WO2026015087A1 (en) * | 2024-07-12 | 2026-01-15 | National University Of Singapore | A method for determining a subject's responsiveness to treatment with a vegf inhibitor |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2004108896A2 (en) | 2003-06-03 | 2004-12-16 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| BRPI0511088A (pt) | 2004-05-14 | 2007-12-26 | Monica Nister | identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib |
| AU2005263972A1 (en) | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
| JP2008518610A (ja) | 2004-11-03 | 2008-06-05 | アルマック ダイアグノスティックス リミテッド | トランスクリプトームマイクロアレイ技法およびそれを使用する方法 |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| US20080305962A1 (en) | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US7919261B2 (en) | 2005-12-05 | 2011-04-05 | Merck Sharp & Dohme Corp. | Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers |
| JP2009524438A (ja) | 2006-01-27 | 2009-07-02 | トライパス イメージング インコーポレイテッド | 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物 |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP2074226A2 (en) | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| NZ582941A (en) | 2007-08-13 | 2012-05-25 | Almac Diagnostics Ltd | A 3' -based sequencing approach for microarray manufacture |
| WO2009061800A2 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| WO2009149297A1 (en) | 2008-06-04 | 2009-12-10 | The Arizona Board Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
| ES2552937T3 (es) | 2008-06-06 | 2015-12-03 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Factor de predicción de supervivencia para linfoma difuso de células B grandes |
| CA2730614A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| DK2368118T3 (da) | 2008-12-23 | 2013-11-25 | Merck Patent Gmbh | Biomarkører til inhibitorer med anti-angiogen aktivitet |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| EP2425020A4 (en) | 2009-05-01 | 2016-04-20 | Genomic Health Inc | GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| KR101557545B1 (ko) | 2009-09-17 | 2015-10-06 | 에프. 호프만-라 로슈 아게 | 암 환자에서 진단 용도를 위한 방법 및 조성물 |
| EP2975399B1 (en) | 2010-09-15 | 2022-05-11 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CA2862835A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| HK1214633A1 (zh) * | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
-
2014
- 2014-05-28 GB GBGB1409479.1A patent/GB201409479D0/en not_active Ceased
-
2015
- 2015-02-09 WO PCT/GB2015/050352 patent/WO2015118353A1/en not_active Ceased
- 2015-02-09 KR KR1020167024823A patent/KR20160117606A/ko not_active Withdrawn
- 2015-02-09 CN CN201580016568.5A patent/CN106164296A/zh active Pending
- 2015-02-09 BR BR112016018044A patent/BR112016018044A2/pt not_active IP Right Cessation
- 2015-02-09 AU AU2015213844A patent/AU2015213844A1/en not_active Abandoned
- 2015-02-09 CA CA2938807A patent/CA2938807A1/en not_active Abandoned
- 2015-02-09 EP EP15705693.8A patent/EP3102700A1/en not_active Withdrawn
- 2015-02-09 US US15/116,641 patent/US10280468B2/en not_active Expired - Fee Related
- 2015-02-09 JP JP2016550631A patent/JP2017506506A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Kalathil et al. | Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy | |
| Yuan et al. | The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | |
| Dillon et al. | ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment | |
| Simeone et al. | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma | |
| Duruisseaux et al. | Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis | |
| Kim et al. | Immune checkpoint inhibitors for urothelial carcinoma | |
| Polivka Jr et al. | Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme | |
| JP2014516552A5 (enExample) | ||
| Chen et al. | Changes of CD4+ CD25+ FOXP3+ and CD8+ CD28− regulatory T cells in non-small cell lung cancer patients undergoing surgery | |
| Sundar et al. | Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers | |
| Marchetti et al. | Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones | |
| Yang et al. | Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies | |
| Zhao et al. | Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1 | |
| JP2015536667A5 (enExample) | ||
| JP2017530372A5 (enExample) | ||
| Tegos et al. | Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma | |
| Sionakidis et al. | Unravelling the tangled web of hypertension and cancer | |
| Ring et al. | Potential immunotherapy targets in recurrent cervical cancer | |
| Vidwans et al. | A framework for genomic biomarker actionability and its use in clinical decision making | |
| Ramaswami et al. | Novel cancer therapies: treatments driven by tumour biology | |
| Riehmer et al. | Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma | |
| Gridelli et al. | Erlotinib in the treatment of non-small cell lung cancer: current status and future developments | |
| Kong et al. | TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC | |
| Zhong et al. | Immunotherapy for small cell lung cancer: current challenges and prospects |